Current Report Filing (8-k)
September 16 2020 - 08:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
September 16, 2020
GALERA THERAPEUTICS, INC.
(Exact name of registrant as specified in its
charter)
|
|
|
|
|
Delaware |
|
001-39114 |
|
46-1454898 |
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
2 W Liberty Blvd #100
Malvern, PA 19355
(Address of principal executive offices) (Zip
Code)
(610) 725-1500
(Registrant’s telephone number, include area
code)
N/A
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to
Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, $0.001 par value
per share |
|
GRTX |
|
The Nasdaq Global
Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 7.01. |
Regulation FD Disclosure.
|
Galera Therapeutics, Inc. (the “Company”) from time to time
presents and/or distributes to the investment community at various
industry and other conferences slide presentations to provide
updates and summaries of its business. On September 16, 2020,
the Company posted an updated corporate slide presentation in the
“Investors” portion of its website at www.galeratx.com. A
copy of its current corporate slide presentation is attached to
this Current Report on Form 8-K as Exhibit 99.1. The Company
undertakes no obligation to update, supplement or amend the
materials attached hereto as Exhibit 99.1.
The information contained in Item 7.01 of this Form 8-K (including Exhibit 99.1 attached
hereto) shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except
as expressly provided by specific reference in such a filing.
Item 9.01. |
Financial Statements and Exhibits.
|
(d) Exhibits
The following exhibit relating to Item 7.01 shall be deemed to be
furnished, and not filed:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
GALERA THERAPEUTICS, INC. |
|
|
|
|
Date: September 16, 2020 |
|
|
|
By: |
|
/s/ J. Mel Sorensen, M.D.
|
|
|
|
|
|
|
J. Mel Sorensen, M.D. |
|
|
|
|
|
|
President and Chief Executive Officer |